We welcome patients, friends, family, caregivers and medical professionals to get involved in our research and benefit the health of our community and world.
BEST-CLI This study will compare the effectiveness of best available surgical treatment with best available endovascular treatment in adults with critical limb ischemia (CLI) who are eligible for both treatment options.
dal-GenE Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)Acute Coronary Syndrome.
DREAM-HF-1 The primary objective of this study is to determine whether the investigational transendocardial delivery of allogeneic human bone marrow-derived MPCs (rexlemestrocel-L) is effective for chronic heart failure due to LV systolic dysfunction.
“WE WEREN'T A BIT AFRAID.”
“AT NEARLY 400 POUNDS, I CONSTANTLY WONDERED IF THERE WAS STILL HOPE FOR A HEALTHIER ME.”
— MARCUS MCCLEARY: ATRIAL FIBRILLATION | See Full Story ›
“I WAS SCARED TO DEATH BUT DR. SCHWARTZ ASSURED ME THAT EVERYTHING WOULD BE FINE.”
— DANIEL SEMAN: CORONARY ARTERY DISEASE | See Full Story ›
We have conducted hundreds of studies covering a wide spectrum of disease prevention and cardiovascular care. Our work is made possible through key partnerships, institutional review boards, and our access to a complex set of data via national registries and databases.
With 35 years of experience and the expertise of key thought leaders and physicians, we enroll nearly 1,000 research subjects every year. Our highly educated and experienced staff uses the momentum of achievement and an overarching dedication to patient care to propel our work forward.